AUG 5·SEC EDGARLow
Chao Xingjuan sold $714K of CBLL
Chao Xingjuan (President and CEO) sold 39,000 shares of Ceribell, Inc. (CBLL) at $18.32 ($0.71M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Medical Devices
$CBLL
Ceribell, Inc.
Price · $CBLLvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $714K 1 txs
Chao Xingjuan1× · $714K
10b5-1 plan100%
Top stories · $CBLLMore →
AUG 3·investing.com
CeriBell stock rises after securing Medicare payment approval
CeriBell Inc. (NASDAQ:CBLL) shares rose about 3% after CMS approved a New Technology Add-on Payment for its Delirium Monitor System. The NTAP allows up to $2,171 per eligible Medicare patient case, starting Oct. 1, 2026, following FDA 510(k) clearance in Dec. 2025.
JUL 29·SEC EDGAR 8-K
Ceribell, Inc. (CBLL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001861107 0001861107 2026-07-28 2026-07-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28,
CBLL sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning CBLL (Ceribell, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CBLL coverage spans insider activity, regulation and corporate actions.
In the last 30 days, CBLL insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($714K). The most active reporter was Chao Xingjuan, President and CEO, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving CBLL
This is a routine, pre-arranged insider sale with no stated operational or financial catalyst.
CMS NTAP approval should improve Medicare reimbursement economics for CeriBell’s Delirium Monitor System starting Oct. 1, 2026.
Board rebalancing and new director appointments are unlikely to change near-term fundamentals, but they can affect governance, committee oversight, and director compensation optics.
This is an insider open-market sale under a pre-arranged 10b5-1 plan, which is typically lower-signal than discretionary selling.
Routine insider selling via an indirect holder; likely limited incremental signal absent other corroborating changes.
alphai scores every news story that mentions CBLL with an AI model for sentiment and relevance, and aggregates insider trades from Ceribell, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CBLL
Score
Chao Xingjuan sold $714K of CBLL
Chao Xingjuan (President and CEO) sold 39,000 shares of Ceribell, Inc. (CBLL) at $18.32 ($0.71M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readCeriBell stock rises after securing Medicare payment approval
CeriBell Inc. (NASDAQ:CBLL) shares rose about 3% after CMS approved a New Technology Add-on Payment for its Delirium Monitor System. The NTAP allows up to $2,171 per eligible Medicare patient case, starting Oct. 1, 2026, following FDA 510(k) clearance in Dec. 2025.
3 min readCeribell, Inc. (CBLL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001861107 0001861107 2026-07-28 2026-07-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28,
3 min readChao Xingjuan sold $776K of CBLL
Chao Xingjuan (President and CEO) sold 39,000 shares of Ceribell, Inc. (CBLL) at $19.90 ($0.78M total) across 3 trades on 2026-07-07 under a Rule 10b5-1 trading plan.
2 min readTPG GP A, LLC sold $4.1M of CBLL (indirect holdings)
TPG GP A, LLC sold 202,368 indirectly-held shares of Ceribell, Inc. (CBLL) at $20.12 ($4.07M total) on 2026-06-26.
2 min readTaylor Joseph Michael sold $101K of CBLL
Taylor Joseph Michael sold 5,500 shares of Ceribell, Inc. (CBLL) at $18.41 ($0.10M total) on 2026-06-11.
1 min readChao Xingjuan sold $715K of CBLL
Chao Xingjuan (President and CEO) sold 39,000 shares of Ceribell, Inc. (CBLL) at $18.33 ($0.71M total) across 3 trades on 2026-06-08 under a Rule 10b5-1 trading plan.
1 min read
CeriBell (NASDAQ:CBLL) VP Sells $16,205.60 in Stock
CeriBell (NASDAQ:CBLL) VP David Foehr sold 862 shares on May 22 at an average $18.80 for $16,205.60, filing the trade with the SEC. The sale was to cover tax withholding tied to equity vesting, reducing his direct stake by 2.23% to 37,751 shares. CeriBell reported May 11 quarterly EPS of -$0.52 on $26.49M revenue.
2 min readManni Joseph S. sold $25K of CBLL
Manni Joseph S. (Chief Revenue Officer) sold 1,378 shares of Ceribell, Inc. (CBLL) at $18.00 on 2026-05-21.
2 min readFoehr David sold $18K of CBLL
Foehr David (Senior VP, Finance and PAO) sold 987 shares of Ceribell, Inc. (CBLL) at $18.00 on 2026-05-21 under a Rule 10b5-1 trading plan.
1 min read